An Open-label Study to Assess the Pharmacokinetic Interaction Between Xeloda and Oxaliplatin in Patients With Metastatic Colorectal Cancer
Latest Information Update: 27 Jan 2016
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Pharmacokinetics
- Sponsors Roche
- 18 Aug 2008 Actual patient number (64) reported by ClinicalTrials.gov.
- 18 Aug 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 30 May 2007 New trial record.